SINGAPORE (June 18): When Singapore-based Aslan Pharmaceuticals made its debut on the Nasdaq Global Market on May 4, one of its investors, Abel Ang, was confident it would do well despite the fact that it sold less 1.5 million American Depository Shares than originally planned. A month on, shares in Aslan — a biotech firm that develops immunotherapies targeted at Asia-prevalent tumour types — are up 25% to trade at US$8.83 on June 12, and at least four banks are bullish on the stock. Ang, CEO of Accuron Medtech, is now on the lookout for more of such medical technology (medtech) companies.

Have a premium account? Sign in to continue reading.

Unlimited access to all stories from $99.9/year*

The latest reporting and analysis from business and investments to news and views on social issues.


  • Simultaneous logins across all devices
  • Instant access to past digital issues
  • Unlimited access to The Edge Malaysia
  • *For annual subscription plan only. T&Cs apply